What Carim 200 Treats: Main Uses and Benefits

The primary therapeutic role of Carim 200 (Modafinil) is to act as a wakefulness-promoting agent, generally applied across domains where additional symptomatic support is needed for chronic conditions characterized by excessive sleepiness.

This medication is commonly used to help with excessive sleepiness in adult patients with specific sleep-wake disorders. The conditions where Carim 200 is generally applied include narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS)-related residual sleepiness, and shift work sleep disorder (SWSD).

The medication helps address symptom clusters that may become intense or disruptive, such as the severe, persistent urges to sleep and impaired vigilance. It provides supportive relief when symptoms interfere with routine activities, contributing to a sense of stability during symptomatic periods. The use is generally focused on managing symptoms related to noticeable functional strain caused by sleepiness.

“The central benefit is the promotion of wakefulness, assisting with managing symptoms that interfere with daily comfort and contributing to easing the overall symptom load associated with sleepiness.”

Quick Fact: Relief for Excessive Daytime Sleepiness

Carim 200 is used for managing the core symptom of excessive daytime sleepiness (EDS) in patients where this manifestation is tied to a specific chronic sleep-wake regulation disorder. This supportive action may assist with maintaining functional stability during required waking hours.

Regulatory References

1. NIH DailyMed Label Information

Eligibility Map: Who Can and Cannot Use Carim 200 — Official Regulatory Information

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult patients with excessive sleepiness associated with Narcolepsy, Obstructive Sleep Apnea (OSA), or Shift Work Disorder (SWD).

Populations for whom use is not recommended (if applicable):

• Pediatric patients (under 17 or 18 years).
• Pregnant women and women who may become pregnant.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to the active substance modafinil or to armodafinil.
• Patients with a history of Left Ventricular Hypertrophy or uncontrolled moderate to severe hypertension or cardiac arrhythmias.

Age-related eligibility rules:

• Pediatric Use: Use is not recommended as safety and effectiveness have not been established.
• Geriatric Use (ge 65 years): A lower starting dose is recommended due to potential for reduced clearance.

Condition-specific eligibility rules:

• Severe Hepatic Impairment: Requires a mandatory dose reduction to half the usual recommended amount.
• Psychiatric History: Use should be with caution in patients with a history of psychosis, depression, mania, or substance abuse.

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: Contraindicated in some regions; women of childbearing potential must use effective non-hormonal contraception during treatment and for two months after stopping.
• Lactation: Use is not recommended.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated (e.g., Hypersensitivity).
• Not Recommended (e.g., Pediatric patients).
• Dose Modification Required (e.g., Severe Hepatic Impairment).

Connection to the overall eligibility profile: Regulatory labeling strictly defines who can and cannot use the medicine by establishing a clear framework of absolute contraindications, age-related exclusions, and conditional use requirements. This profile is further constrained by mandated dose adjustments for impaired organ function and specific monitoring requirements for patients with a history of certain psychiatric conditions.

Interactions with other medicines and products

Carim 200 has a documented potential for drug-drug interactions, primarily due to its effects on liver enzyme systems. It is officially identified as both an inducer of certain enzymes, such as CYP3A4/5, and an inhibitor of others, specifically CYP2C19.

---

Clinically Significant Interactions

Interaction Type	Examples of Affected Co-administered Drugs	Official Constraint
Decreased Exposure	Steroidal contraceptives, Cyclosporine, Midazolam	Requires use of non-hormonal contraception; Cyclosporine levels must be monitored.
Increased Exposure	Phenytoin, Omeprazole, Diazepam	Requires monitoring for toxicity or elevated plasma levels.

---

Other Documented Constraints

Because Carim 200 is a potent enzyme inducer, the regulatory label specifies that the efficacy of hormonal contraceptives (e.g., those containing ethinyl estradiol) may be significantly reduced. Patients are advised to use reliable, non-hormonal methods of contraception during treatment and for one month after discontinuation of Carim 200. Concomitant use with alcohol is officially discouraged. For patients with severe hepatic impairment, the official label notes a significant decrease in drug clearance, necessitating the use of a lower starting dose.

Carim 200 (Modafinil) is a wakefulness-promoting compound whose action is driven by a complex mechanism targeting key regulatory systems within the Central Nervous System (CNS).

Modulation of Arousal Transporters

The compound acts as a weak, selective competitive inhibitor of the Dopamine Transporter (DAT). By temporarily blocking the DAT, the drug slows the reabsorption of dopamine into the neuron. This molecular action leads to increased dopamine availability in the synapse, increasing the downstream signaling capacity for the maintenance of an alert state. The drug utilizes a racemic mixture, where the R-enantiomer displays a higher affinity for this transporter than the S-enantiomer.

Amplification of Hypothalamic Arousal Centers

The core physiological effect stems from the drug's ability to activate specialized nerve cells in the hypothalamus that release Orexin (Hypocretin). Orexin acts as a key signaling mediator, cascading into increased release of Histamine and Norepinephrine in the neuronal pathways that regulate the sleep-wake cycle. This amplification contributes to a functional shift in the neurochemical balance favoring wakefulness.

Resulting Sustained CNS Vigilance

The coordinated effect of increased dopamine and the specific activation of the orexin-histamine centers results in a sustained stabilization of the CNS state favoring wakefulness. The unique interaction profile of the drug does not lead to the rapid, widespread monoamine release characteristic of other agents, thereby generating a focused state of central nervous system arousal that is governed by specific regulatory pathways.

Carim 200 (modafinil) is formulated as an oral tablet and is administered via the oral route. The medicine is supplied in specific tablet strengths, commonly including 100 mg and 200 mg, and should be swallowed whole, regardless of whether it is taken with or without food. The standard administration pattern involves a daily dose of 200 mg taken once daily. Although doses up to 400 mg per day have been used, no consistent evidence supports additional therapeutic benefit beyond the 200 mg dose for most uses.

The timing of the daily dose is conditional on the patient’s specific condition. For use related to conditions like narcolepsy, the dose is typically taken once in the morning. In contrast, for shift work sleep disorder, the dose is scheduled to be taken approximately one hour prior to the commencement of the work shift to support wakefulness during the required hours.

Dosing regimens require modification for specific populations. For instance, the daily dose must be formally reduced by half (to 100 mg) for patients who have severe hepatic impairment. Similarly, a lower initial dose, such as 100 mg per day, is recommended for older adults (65 years and over). Safety and efficacy of this agent have not been established for use in the pediatric population. Because long-term use has not been fully evaluated in clinical trials beyond 9 to 12 weeks, the need for continued treatment requires periodic re-evaluation by a physician.

Research evidence / Overview of studies for Carim 200

Evidence for Use in Narcolepsy

Research into Carim 200 (modafinil) has extensively studied its use in adult patients with narcolepsy, a condition characterized by fluctuating or episodic manifestations of excessive daytime sleepiness. The research base includes multiple Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These short-term trials were used in research exploring how symptoms change over time, alongside long-term open-label studies.

The studies examined objective measures of wakefulness, such as the Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT), as well as patient-reported outcomes describing perceived discomfort and overall daily functioning. Reports from the core RCTs described measurements of increased sleep latency on objective tests compared to those receiving placebo. Research highlights changes measured during the study period, contributing to understanding how patients reported their experience regarding daytime alertness.

Evidence for Use in OSAHS-Related Sleepiness

Carim 200 was evaluated in research exploring its use as an adjunctive treatment for adult patients with excessive sleepiness associated with Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS). The evidence base for this context consists primarily of Randomized, Double-Blind, Placebo-Controlled Trials conducted during periods where patients were already receiving and compliant with standard therapy, such as Continuous Positive Airway Pressure (CPAP). Research monitored objective measures of wakefulness and outcomes reflecting daily functioning or activity level.

Reports documented differences in objective sleep latency measurements and subjective sleepiness scores when compared to placebo in patients receiving stable CPAP. Crucially, studies consistently reported that the medicine was not studied as a substitute for CPAP or as a primary therapy for the underlying respiratory cause of OSAHS. This medicine was studied for managing the residual symptom of sleepiness, not the underlying functional imbalance.

Key Research Gaps and Uncertainties

Despite the existence of multiple high-quality RCTs, several key research gaps and uncertainties remain in the evidence base. The primary limitation is that follow-up durations were limited in the core controlled studies, and long-term effects are not fully established regarding sustained effectiveness. Additionally, for the OSAHS and SWSD indications, international regulatory interpretation of the evidence has varied. Research does not fully characterize the medicine's role in the core circadian rhythm disruption that defines Shift Work Sleep Disorder (SWSD).

Key Studies & References

1. PROVIGIL (modafinil) tablets: Full Prescribing Information

Common questions about Carim 200 (FAQ)

---

Q: How quickly should I expect to see any effects from Carim 200?

Official product information describes the medicine’s absorption and distribution in the body. According to this data, the highest levels of the medicine in the blood, known as peak plasma concentrations, typically occur within 2 to 4 hours after a dose is taken. Taking the medicine with food may slow down this process by approximately one hour.

---

Q: What are the most commonly reported less-serious side effects of Carim 200?

Regulatory documents list the most frequently reported less-serious effects, often referred to as common adverse reactions. These generally involve the nervous and gastrointestinal systems, and commonly include headache, nausea, nervousness, insomnia (difficulty sleeping), and dizziness.

---

Q: Can Carim 200 cause changes in appetite or weight?

Official documents note that a decrease in appetite is a commonly reported effect in patients taking this medicine. However, during the clinical trials involving adults, official research did not generally observe significant changes in overall body weight.

---

Q: Can Carim 200 be taken with heart medications?

The medicine can potentially increase heart rate and blood pressure, which is a key safety consideration. Because of this cardiovascular risk, official guidance states that increased monitoring is recommended when the medicine is used in patients with known pre-existing heart or cardiovascular conditions.

---

Q: Can taking Carim 200 with pain relievers, like ibuprofen, be an issue?

The medicine is officially described as an inhibitor of certain liver enzymes, specifically CYP2C19. For other prescription drugs processed by this enzyme, official labeling recommends monitoring for elevated levels. Specific warnings for every over-the-counter pain reliever are not addressed in regulatory warnings.

---

Q: What does the term 'Drug A is metabolized by the same enzyme as Carim 200' mean for interactions?

This means that both substances are processed by the same detoxification system in the liver, such as enzymes like CYP3A4 or CYP2C19. When this happens, Carim 200 can change the speed at which the other substance is broken down. This may result in the affected substance having either decreased or increased levels in the body, which then requires monitoring.

---

Q: What is the typical timeframe for most common side effects to go away after starting Carim 200?

Regulatory documents do not specify a typical timeframe for the resolution of common, less serious effects like headache or nausea. However, it is noted that the most serious and rare side effects, such as a severe skin rash, are generally observed to occur within the first 1 to 5 weeks of treatment initiation.

---

Q: Is Carim 200 safe for patients with kidney problems?

Official documents indicate that there is inadequate information to fully determine the safety and efficacy of dosing for patients with general renal impairment (kidney problems). However, a major component of the medicine does increase substantially in patients with kidney insufficiency, suggesting caution is necessary.

---

Q: What is the longest time a person can generally take Carim 200?

The long-term safety and effectiveness of the medicine have not been conclusively established in controlled trials lasting longer than 9 to 12 weeks. Because of this, official guidelines state that physicians prescribing the medicine for an extended time should periodically re-evaluate the need for continued treatment.

---

Q: Does Carim 200 have a risk of becoming dependent on it?

The medicine is classified as a Schedule IV controlled substance in the United States. This classification indicates that the medicine has a recognized medical use but also carries a potential for abuse and dependence, which is generally considered lower than Schedule II or III substances.

---

Q: Can Carim 200 change the way my body reacts to caffeine?

Official warnings state that combining the medicine with beverages or foods containing caffeine may enhance the stimulant effects of both substances. This combination could potentially increase the risk of specific side effects like anxiety, nervousness, or trouble sleeping.

---

Q: I've heard Carim 200 is similar to Drug X; how do official documents describe the difference?

Regulatory documents describe the medicine as a Wakefulness-Promoting Agent that is structurally unique from classical Central Nervous System (CNS) stimulants, such as amphetamines. Its mechanism of action is considered more targeted, involving selective actions on specific pathways that regulate the sleep-wake cycle.

---

Q: What does the research say about Carim 200's effectiveness over a long period?

Controlled clinical trials for the medicine were generally limited to short durations, typically 9 to 12 weeks. This means that the sustained effectiveness of the medicine beyond this short-term period has not been fully established in controlled clinical research.

---

Q: Can Carim 200 affect sleep patterns, like causing insomnia or making me drowsy?

Official labeling lists Insomnia (difficulty sleeping) as one of the most frequently reported side effects of the medicine. However, as its core purpose is to promote wakefulness, the medicine is not typically associated with causing excessive daytime drowsiness.

---

Q: What should I do if I miss a dose of Carim 200?

The official label provides general instructions for missed doses, which typically state that only the next scheduled dose should be taken if the previous one was forgotten. Patients should adhere to their prescribed regimen and avoid taking a double or extra dose.

---

Q: Does Carim 200 affect driving ability or concentration?

Official warnings state that the medicine may affect coordination, reaction time, or judgment. Patients should be aware of this potential risk before driving or operating heavy machinery.

---

Q: What is the difference between Carim 200 and a placebo in clinical trials?

Studies and official information indicate that patients receiving the medicine in controlled trials demonstrated measurements of increased sleep latency (a greater ability to stay awake) and improved subjective sleepiness scores when compared to those receiving an inactive placebo.

---

Q: Why is 200 the number used in the name Carim 200?

The number '200' in the product name is commonly used to designate the recommended standard daily dose of the active ingredient, which is 200 mg. The medicine is also often available in other tablet strengths.

---

Q: What are the signs of a possible allergic reaction to Carim 200?

Signs of a serious allergic or hypersensitivity reaction can be diverse but often include the sudden onset of fever and a rash associated with other organ system involvement. Swelling of the face, lips, or tongue, and trouble breathing have also been reported.

---

Q: Is Carim 200 available as a generic version?

Yes, official drug authority records indicate that the active ingredient in Carim 200 (modafinil) has been approved to be available in generic tablet versions in the United States and other international regions.

How to Store and Dispose of Carim 200 (Modafinil)

The following instructions for storing and disposing of Carim 200 tablets are based strictly on official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Requirement	Condition
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep away from excess heat and moisture; do not store in the bathroom.
Container	Keep the medicine in its original container and ensure it is tightly closed.
Child Safety	Must be kept out of the sight and reach of children and secured from theft.

Official Disposal Protocol

Unused or expired Carim 200 should be disposed of in accordance with local regulations, generally by utilizing a drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance, sealed in a bag or container, and discarded in the household trash. The medication must not be flushed down the toilet or poured down a sink.